Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-798

https://www.*.com.au/coronavirus-vaccine-may-be-impossible-to-produce-scientists-covid-2020-4?r=US&IR=T

All those holders (and others) best hope MSB gets picked up by medical and political factions, because the future does not look bright without a cure. Just because 100 or so companies are pursuing a vaccine, doesn't mean any of them will be successful.

Low anti-bodies in previously infected patients fall below the traditional thresholds for vaccines. If having the virus doesn't encourage sufficient antibodies it will be difficult for a vaccine to do so.

I though re-purposed drugs might be the best bet for COVID-19 (Ivermictin particularly) to slow cellular replication of COVID-19, until I saw MSB had been accepted for FDA trials (that in itself was a surprise). Roll on the wider trial results and a new trial in non-ARDS patients and we might (if we are lucky) not only have a winner, but also a potential way out of this pandemic - if critical cases are treatable and deaths kept below influenza levels (cytokines and ARDS a common factor in deaths there too, so MSB could have wider benefits beyond COVID-19) then the authorities might be willing to let heard immunity to occur and we get out of this economic, social and morbid quagmire.

People need to revisit the original stats and reports that drove lock-downs. Lock-downs were only ever going to slow this thing until herd immunity or a vaccine prevailed. MSB makes the former feasible.